Pharsight

Drugs that contain Cedazuridine; Decitabine

1. List of Inqovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9567363 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(5 years from now)

US8268800 OTSUKA Certain compounds, compositions and methods
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618075 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 7, 2025
Orphan Drug Exclusivity (ODE) Jul 7, 2027

NCE-1 date: 2024-07-07

Market Authorisation Date: 07 July, 2020

Treatment: Method for inhibiting cytidine deaminase by administering cedazuridine; Method for inhibiting degradation of a cda substrate by administering cedazuridine; Treatment of chronic myelomonocytic leukemia...

Dosage: TABLET;ORAL

More Information on Dosage

INQOVI family patents

6

United States

2

Spain

2

Japan

2

European Union

1

Israel

1

South Africa

1

Denmark

1

Austria

1

Mexico

1

Australia

1

Saudi Arabia

1

Hong Kong

1

Slovenia

1

Jordan

1

Costa Rica

1

Colombia

1

Croatia

1

Brazil

1

Guatemala

1

Portugal

1

Cyprus

1

Malaysia

1

Korea, Republic of

1

Poland

1

Taiwan, Province of China

1

RS

1

Ecuador

1

Nicaragua

1

China

1

Ukraine

EA

1

EA

1

Canada

1

New Zealand

1

ME

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic